Tripep – Financial update

In January 2008 Tripep finalized a rights offering which raised almost SEK 16 m. Since one of the guarantors, Rutger Smith, did not fulfill his commitment, the rights issue was SEK 8 m less than expected. As a result Tripep’s liquid assets will not cover the current capital requirements until the next rights issue has been completed. Some of the major suppliers have agreed to postpone their invoicing pending the capital injection from the upcoming rights issue. This will enable us to continue the ongoing clinical trial of the therapeutic vaccine, ChronVac-C® without delay. Tripep’s claim on the guarantor Rutger Smith remains unchanged. Tripep is planning a rights issue during the third quarter 2008. The precise conditions of the rights issue will be published later.

“Our projects, spearheaded by ChronVac-C®, now generate very interesting data and are running according to plan, hence we feel optimistic that we will succeed in capitalizing the company despite the unfulfilled engagement from one of our guarantors”, says Tripep’s CEO Jan Nilsson.


For more information, please contact:
Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se

About Tripep
Tripep develops drugs against chronic disease based on proprietary and other parties’ patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal and a therapeutic vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company’s website: www.tripep.se.